BioInvent International AB (BINV) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.082x

Based on the latest financial reports, BioInvent International AB (BINV) has a cash flow conversion efficiency ratio of 0.082x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr66.78 Million ≈ $7.19 Million USD) by net assets (Skr810.74 Million ≈ $87.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See BINV days of operational coverage to measure how many days the company can operate on defensive assets alone.

BioInvent International AB - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how BioInvent International AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

BioInvent International AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of BioInvent International AB ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
NASDAQ:OACC
-0.001x
HUYA Inc
F:HY5A
N/A
Solara Active Pharma Sciences Limited
NSE:SOLARA
0.059x
Sierra Madre Gold and Silver Ltd
V:SM
0.067x
Alfen Beheer BV
AS:ALFEN
0.070x
Circio Holding ASA
OL:CRNA
2.054x
Sheng Yu Steel Co Ltd
TW:2029
-0.002x
Yantai Changyu Pioneer Wine
SHE:200869
0.012x

Annual Cash Flow Conversion Efficiency for BioInvent International AB (2002–2024)

The table below shows the annual cash flow conversion efficiency of BioInvent International AB from 2002 to 2024. For the full company profile with market capitalisation and key ratios, see BINV market cap.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 Skr885.82 Million
≈ $95.33 Million
Skr-380.47 Million
≈ $-40.94 Million
-0.430x -64.64%
2023-12-31 Skr1.31 Billion
≈ $140.95 Million
Skr-341.69 Million
≈ $-36.77 Million
-0.261x -916.36%
2022-12-31 Skr1.61 Billion
≈ $172.84 Million
Skr-41.23 Million
≈ $-4.44 Million
-0.026x +85.73%
2021-12-31 Skr1.37 Billion
≈ $147.11 Million
Skr-245.84 Million
≈ $-26.46 Million
-0.180x -113.52%
2020-12-31 Skr743.50 Million
≈ $80.01 Million
Skr-62.62 Million
≈ $-6.74 Million
-0.084x +88.62%
2019-12-31 Skr169.44 Million
≈ $18.23 Million
Skr-125.43 Million
≈ $-13.50 Million
-0.740x +54.13%
2018-12-31 Skr87.62 Million
≈ $9.43 Million
Skr-141.39 Million
≈ $-15.22 Million
-1.614x -176.96%
2017-12-31 Skr130.22 Million
≈ $14.01 Million
Skr-75.88 Million
≈ $-8.17 Million
-0.583x -86.35%
2016-12-31 Skr230.44 Million
≈ $24.80 Million
Skr-72.05 Million
≈ $-7.75 Million
-0.313x +87.31%
2015-12-31 Skr29.45 Million
≈ $3.17 Million
Skr-72.57 Million
≈ $-7.81 Million
-2.464x -69.91%
2014-12-31 Skr52.43 Million
≈ $5.64 Million
Skr-76.03 Million
≈ $-8.18 Million
-1.450x -30.04%
2013-12-31 Skr49.01 Million
≈ $5.27 Million
Skr-54.65 Million
≈ $-5.88 Million
-1.115x +68.83%
2012-12-31 Skr47.62 Million
≈ $5.13 Million
Skr-170.38 Million
≈ $-18.34 Million
-3.578x -790.00%
2011-12-31 Skr137.95 Million
≈ $14.85 Million
Skr-55.45 Million
≈ $-5.97 Million
-0.402x +74.66%
2010-12-31 Skr74.19 Million
≈ $7.98 Million
Skr-117.70 Million
≈ $-12.67 Million
-1.586x +30.58%
2009-12-31 Skr55.63 Million
≈ $5.99 Million
Skr-127.14 Million
≈ $-13.68 Million
-2.285x -1308.90%
2008-12-31 Skr231.30 Million
≈ $24.89 Million
Skr43.73 Million
≈ $4.71 Million
0.189x +220.57%
2007-12-31 Skr214.12 Million
≈ $23.04 Million
Skr12.63 Million
≈ $1.36 Million
0.059x +106.42%
2006-12-31 Skr110.15 Million
≈ $11.85 Million
Skr-101.23 Million
≈ $-10.89 Million
-0.919x -90.80%
2005-12-31 Skr219.00 Million
≈ $23.57 Million
Skr-105.48 Million
≈ $-11.35 Million
-0.482x -15.43%
2004-12-31 Skr212.68 Million
≈ $22.89 Million
Skr-88.74 Million
≈ $-9.55 Million
-0.417x -92.09%
2003-12-31 Skr304.96 Million
≈ $32.82 Million
Skr-66.25 Million
≈ $-7.13 Million
-0.217x -710.31%
2002-12-31 Skr394.25 Million
≈ $42.43 Million
Skr-10.57 Million
≈ $-1.14 Million
-0.027x --

About BioInvent International AB

ST:BINV Sweden Biotechnology
Market Cap
$210.68 Million
Skr1.96 Billion SEK
Market Cap Rank
#16440 Global
#270 in Sweden
Share Price
Skr29.75
Change (1 day)
+1.02%
52-Week Range
Skr21.25 - Skr41.05
All Time High
Skr95.26
About

BioInvent International AB (publ), a clinical-stage company, discovers and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. The company's drug candidates include BI-1808, an anti- tumor necrosis factor receptor-2 (TNFR2) antibody in Phase 2a trial for the treatment of solid tumors and a type of blood cancer; BI-1206, an a… Read more